AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19785568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 857
Study 19785568 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg/day
Number of subjects: 857
Study 19785568 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day
Number of subjects: 857
Study 17207073 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin cream (0.075%) applied unilaterally to the mental area, four times daily for 2 weeks
Number of subjects: 20
Study 17207073 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin cream (0.075%)
Number of subjects: 20
Study 15347608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric ropivacaine 10 mg/ml (1.5 ml) with glucose 300 mg/ml (0.5 ml)
Number of subjects: 56
Study 15347608 — intervention group
Group type: COMPARATOR
Intervention: Plain ropivacaine 7.5 mg/ml (2 ml)
Number of subjects: 56
Study 11291821 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisting task with a moment of 20 Nm for 20 min at 10 repetitions min(‐1)
Number of subjects: 20
Study 11291821 — intervention group
Group type: COMPARATOR
Intervention: Lateral bend task with a moment of 20 Nm for 20 min at 10 repetitions min(‐1)
Number of subjects: 20
Study 11291821 — intervention group
Group type: COMPARATOR
Intervention: Flexion task with a moment of 20 Nm for 20 min at 10 repetitions min(‐1)
Number of subjects: 20
Study 9869959 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency pacing (HFP) at 50 Hz, 10 mA, applied at the high right atrium with burst durations of 500, 1000, 2000, and 4000 ms.
Number of subjects: 22
Study 9869959 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency pacing (HFP) at 50 Hz, 10 mA, applied at the high right atrium.
Number of subjects: 22
Study 8323840 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 42
Study 8323840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3548803 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (AD and estimated weight reported)
Number of subjects: 2771
Study 3548803 — intervention group
Group type: COMPARATOR
Intervention: Control group (AD and estimated weight withheld)
Number of subjects: 2771
Study 31402538 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 5 mg, 10 mg, or 25 mg once daily
Number of subjects: 84
Study 31402538 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg once daily
Number of subjects: 84
Study 31402538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 27658659 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant ice cream (100 g containing dark cocoa powder, hazelnut, and green tea extracts)
Number of subjects: 14
Study 27658659 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate ice cream (control ice cream)
Number of subjects: 14
Study 25713428 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine-docetaxel plus bevacizumab
Number of subjects: 107
Study 25713428 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine-docetaxel plus placebo
Number of subjects: 107
Study 23597082 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and problem solving treatment (n=314)
Number of subjects: 622
Study 23597082 — intervention group
Group type: COMPARATOR
Intervention: Health brochures (Control group, n=308)
Number of subjects: 622
Study 21568075 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg t.i.d.)
Number of subjects: 110
Study 21568075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine +/‐ ibuprofen
Number of subjects: 110
Study 21568075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril/hydrochlorothiazide +/‐ piroxicam
Number of subjects: 110
Study 21568075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine +/‐ piroxicam
Number of subjects: 110
Study 21568075 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypertensives with no osteoarthritis)
Number of subjects: 110
Study 19159477 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Clinical Pathway (ECP) trained EMS and ER health professionals
Number of subjects: 4895
Study 19159477 — intervention group
Group type: COMPARATOR
Intervention: Non-trained EMS and ER controls
Number of subjects: 4895
Study 16387395 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency training in patient transfer methods (one transfer before and one after training)
Number of subjects: 71
Study 16387395 — intervention group
Group type: COMPARATOR
Intervention: No proficiency training (two transfers before training)
Number of subjects: 71
Study 15190995 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific reminiscence program (life-story approach)
Number of subjects: 101
Study 15190995 — intervention group
Group type: COMPARATOR
Intervention: Friendly discussions (comparison group)
Number of subjects: 101
Study 15190995 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 101
Study 11071672 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy (cisplatin 60 mg/m² on day 1, etoposide 120 mg/m² on days 1-3, concurrent with radiotherapy 50.4 Gy in 28 fractions)
Number of subjects: 488
Study 11071672 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (50.4 Gy in 28 fractions)
Number of subjects: 488
Study 11071672 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy
Number of subjects: 488
Study 11071672 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 488
Study 8851570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg twice daily with food
Number of subjects: 6
Study 8851570 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg once daily with food
Number of subjects: 6
Study 8851570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg twice daily fasting
Number of subjects: 6
Study 8851570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg single dose
Number of subjects: 6
Study 8851570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg single dose
Number of subjects: 6
Study 8851570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg twice daily with high-fat meal
Number of subjects: 6
Study 1315665 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy plus plasmapheresis (plasma exchange)
Number of subjects: 86
Study 1315665 — intervention group
Group type: COMPARATOR
Intervention: Standard drug therapy alone
Number of subjects: 86
Study 6385935 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 2
Study 6385935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31780586 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 92
Study 31780586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 29903344 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT) - aspirin 325 mg and clopidogrel 75 mg
Number of subjects: 576
Study 29903344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity warfarin plus aspirin (INR 1.5 to 2.0)
Number of subjects: 576
Study 29903344 — intervention group
Group type: COMPARATOR
Intervention: Standard warfarin plus aspirin (INR 2.0 to 3.0)
Number of subjects: 576
Study 26701371 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (PTZ)
Number of subjects: 105
Study 26701371 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin (IMP)
Number of subjects: 105
Study 24939671 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline uric acid (UA) levels
Number of subjects: 131
Study 22513699 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine
Number of subjects: 2506
Study 20580349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitz baths with water at a temperature of less than 15 degrees C
Number of subjects: 24
Study 20580349 — intervention group
Group type: COMPARATOR
Intervention: Sitz baths with water temperature above 30 degrees C
Number of subjects: 24
Study 17628650 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-initiated, individually tailored telephone counseling smoking cessation intervention
Number of subjects: 0
Study 17628650 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study 16153204 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid-induced fluorescence cystoscopy (FC) during transurethral resection (TUR)
Number of subjects: 122
Study 16153204 — intervention group
Group type: COMPARATOR
Intervention: Standard white-light endoscopy during transurethral resection (TUR)
Number of subjects: 122
Study 16153204 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid-induced fluorescence cystoscopy (FC) during TUR
Number of subjects: 122
Study 12371711 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour group education on healthy lifestyle
Number of subjects: 72
Study 12371711 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 10422531 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 presentation of automated appointment messages
Number of subjects: 2
Study 10422531 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 presentations of automated appointment messages
Number of subjects: 2
Study 10422531 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 presentations of automated appointment messages
Number of subjects: 2
Study 10422531 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional retrieval support with repetition
Number of subjects: 2
Study 8526179 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with specific hyposensitization (Abelló Lab., Spain) for 12 months
Number of subjects: 35
Study 8526179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 1483486 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1452 50 mg
Number of subjects: 8
Study 1483486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6529162 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride (50 mg)
Number of subjects: 21
Study 6529162 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg)
Number of subjects: 21
Study 31298721 — intervention group
Group type: EXPERIMENTAL
Intervention: RayOne Trifocal
Number of subjects: 30
Study 31298721 — intervention group
Group type: COMPARATOR
Intervention: FineVision POD F
Number of subjects: 30
Study 29396080 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedded behavioral clinician (BC) delivering SBIRT
Number of subjects: 648
Study 29396080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatrician-only delivering SBIRT
Number of subjects: 648
Study 29396080 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 648
Study 27006237 — intervention group
Group type: EXPERIMENTAL
Intervention: HT-enriched biscuits (HT-B)
Number of subjects: 13
Study 27006237 — intervention group
Group type: COMPARATOR
Intervention: Non-enriched biscuits (C-B)
Number of subjects: 13
Study 23895403 — intervention group
Group type: EXPERIMENTAL
Intervention: WDYD intervention (web-based brief alcohol intervention)
Number of subjects: 609
Study 23895403 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 609
Study 21865319 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (280 or 560 mg) every 8 hours for 7 days
Number of subjects: 16
Study 21865319 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (280 mg)
Number of subjects: 16
Study 21865319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19295301 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic interventions for heart rate control and increased pumping ability of the heart; specific interventions not detailed.
Number of subjects: 0
Study 17115269 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational course (n = 80)
Number of subjects: 240
Study 17115269 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure with correct answers (n = 81)
Number of subjects: 240
Study 17115269 — intervention group
Group type: COMPARATOR
Intervention: No intervention (n = 79)
Number of subjects: 240
Study 15669550 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 110
Study 15669550 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 110
Study 11728684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT) at a dosage of 46 Gy
Number of subjects: 715
Study 11728684 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 715
Study 11728684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT)
Number of subjects: 715
Study 9106379 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diphenhydramine
Number of subjects: 30
Study 9106379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9106379 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diphenhydramine
Number of subjects: 30
Study 1494218 — intervention group
Group type: EXPERIMENTAL
Intervention: I system connector (n = 106)
Number of subjects: 230
Study 1494218 — intervention group
Group type: COMPARATOR
Intervention: Luer‐Lock connector (n = 124)
Number of subjects: 230
Study 3885674 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin and ticarcillin
Number of subjects: 17
Study 3885674 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin and ticarcillin
Number of subjects: 17
Study 3885674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 17
Study 31170104 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (0.1%) + hydroxylpropyl methylcellulose instillation without eyelid speculum (group 1)
Number of subjects: 48
Study 31170104 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (0.1%) + hydroxylpropyl methylcellulose instillation with eyelid speculum (group 2)
Number of subjects: 48
Study 31170104 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 48
Study 28671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation (Vt 7 mL/kg-PEEP 5 mm Hg)
Number of subjects: 32
Study 28671879 — intervention group
Group type: COMPARATOR
Intervention: Traditional ventilation (Vt 9 mL/kg-PEEP 0 mm Hg)
Number of subjects: 32
Study 28671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation
Number of subjects: 32
Study 28671879 — intervention group
Group type: COMPARATOR
Intervention: Traditional ventilation
Number of subjects: 32
Study 28671879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ventilation modes
Number of subjects: 32
Study 27112612 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BIV)
Number of subjects: 118
Study 27112612 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical pacing (RVA)
Number of subjects: 118
Study 23903901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal normal saline 5 ml before intrathecal injection of 2.5 ml (12.5 mg) hyperbaric bupivacaine 0.5%
Number of subjects: 100
Study 23903901 — intervention group
Group type: COMPARATOR
Intervention: Control group received 2.5 ml (12.5 mg) hyperbaric bupivacaine 0.5%
Number of subjects: 100
Study 22652586 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 364
Study 22652586 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal allergy
Number of subjects: 364
Study 22652586 — intervention group
Group type: EXPERIMENTAL
Intervention: High OVA IgA antibodies in colostrum
Number of subjects: 364
Study 22652586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of OVA IgA in mature breast milk
Number of subjects: 364
Study 22652586 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β(2) levels in breast milk
Number of subjects: 364
Study 20736446 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (cold saline infusion and endovascular cooling)
Number of subjects: 20
Study 20736446 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 20
Study 18418793 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0
Study 18418793 — intervention group
Group type: COMPARATOR
Intervention: Counseling
Number of subjects: 0
Study 18418793 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR + Counseling
Number of subjects: 0
Study 15845775 — intervention group
Group type: COMPARATOR
Intervention: Anti-G suit inflated to 85 mmHg at 1 G
Number of subjects: 12
Study 15845775 — intervention group
Group type: COMPARATOR
Intervention: Anti-G suit inflated to 85 mmHg at 2 G
Number of subjects: 12
Study 12409170 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week stress management program with follow-up sessions
Number of subjects: 121
Study 12409170 — intervention group
Group type: COMPARATOR
Intervention: Participation in a social activities group
Number of subjects: 121
Study 10047926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine hydrochloride (APO)
Number of subjects: 10
Study 10047926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10047926 — intervention group
Group type: COMPARATOR
Intervention: Optimal doses of carbidopa/levodopa
Number of subjects: 10
Study 7734309 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 436
Study 7734309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 436
Study 7734309 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 436
Study 7734309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological factors (tumour size, macroscopic type, number of sites involved, depth of invasion, involvement of resection lines, lymph nodes, histological grade)
Number of subjects: 436
Study 7734309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lauren classification and histological grade
Number of subjects: 436
Study 7734309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocytic and eosinophilic infiltration, presence of dysplasia
Number of subjects: 436
Study 7734309 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth of invasion, resection line, nodal involvement
Number of subjects: 436
Study 2251632 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic laminaria tent (Lamicel; Cabot)
Number of subjects: 80
Study 2251632 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 (PGE2) oral tablets used intravaginally
Number of subjects: 80
Study 94638 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 12
Study 94638 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 12
Study 94638 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 29581037 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥30)
Number of subjects: 15357
Study 29581037 — intervention group
Group type: COMPARATOR
Intervention: Overweight patients (BMI 25-29.99)
Number of subjects: 15357
Study 29581037 — intervention group
Group type: COMPARATOR
Intervention: Normal weight patients (BMI 18.5-24.99)
Number of subjects: 15357
Study 28153005 — intervention group
Group type: EXPERIMENTAL
Intervention: AbMIP
Number of subjects: 25
Study 26616798 — intervention group
Group type: EXPERIMENTAL
Intervention: APC with medicine group (Esomeprazole 40 mg/d after APC treatment for 8 weeks)
Number of subjects: 61
Study 26616798 — intervention group
Group type: COMPARATOR
Intervention: APC with surgery group (Laparoscopic hiatal hernia repair and Nissen fundoplication after APC treatment)
Number of subjects: 61
Study 24114152 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool Life Skills Program (PLS); teaching strategies included instruction, modeling, role play, and differential reinforcement.
Number of subjects: 12
Study 24114152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PLS program); participated in small-group activities without the intervention.
Number of subjects: 12
Study 21860294 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde voiding trial
Number of subjects: 50
Study 21860294 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous voiding trial
Number of subjects: 50
Study 19820283 — intervention group
Group type: EXPERIMENTAL
Intervention: P-OM3 4 g/day + fenofibrate 130 mg/day
Number of subjects: 167
Study 19820283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 g/day corn oil) + fenofibrate 130 mg/day
Number of subjects: 167
Study 19820283 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-switchers (P-OM3 + fenofibrate) during extension phase
Number of subjects: 167
Study 19820283 — intervention group
Group type: EXPERIMENTAL
Intervention: Switchers (P-OM3 + fenofibrate) during extension phase
Number of subjects: 167
Study 17955091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0
Study 17955091 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0
Study 17955091 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) such as gabapentin and pregabalin
Number of subjects: 0
Study 17955091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15110372 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone View (PV)
Number of subjects: 35
Study 15110372 — intervention group
Group type: COMPARATOR
Intervention: Prone Positioner (PP)
Number of subjects: 35
Study 11298069 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of racemic halofantrine once daily in the fasted state for 42 days
Number of subjects: 21
Study 11298069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9580646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 861
Study 9580646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 861
Study 9580646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study 7905904 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy
Number of subjects: 240
Study 7905904 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 240